Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw to Scientific Advisory Board

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company’s Scientific Advisory Board.

Helix BioPharma Corp. Reports Voting Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and special meeting of shareholders held on January 28, 2021 (the “Meeting”). In accordance with section 11.3 of National …

Helix BioPharma Corp. Responds to Market Activity

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price …

Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.

Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG (“CAIAC”) for the Company’s remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), for gross …

Helix BioPharma Corp. announces fiscal 2021 first quarter results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.

Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno- oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of $1,100,000.

Helix BioPharma Corp. Signs Definitive Agreement to Fully Divest Polish Subsidiary

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG (“CAIAC”), as designed trustee of HIO Fund (the “Fund”), to purchase Helix’s remaining …

Helix BioPharma Corp. provides Polish subsidiary divestiture update

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the remaining shares it holds …

Helix BioPharma Corp. provides Polish subsidiary divestiture update

RICHMOND HILL, ON / ACCESSWIRE / August 31, 2020 – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immunooncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 …